Objectives: Ventilator-associated pneumonia is the most common intensive care unit-acquired infection. Although there is widespread consensus that evidenced-based interventions reduce the risk of ventilator-associated pneumonia, controversy has surrounded the importance of implementing them as a "bundle" of care. This study aimed to determine the effects of implementing such a bundle while controlling for potential confounding variables seen in similar studies.
T he United States-based Institute for Healthcare Improvement (IHI) has championed the "bundle" approach to improving practice and emphasizes the need to achieve high overall compliance rates (preferably 95% compliance with all bundle elements) (1) . Implementing care bundles has been strongly advocated in ventilated intensive care patients, who are at risk for ventilator-associated pneumonia (VAP). VAP is associated with prolonged mechanical ventilation, intensive care unit (ICU) and hospital stay, greater illness costs, and possibly higher mortality (2, 3) . Several clinical interventions have been found to reduce the incidence of VAP, including elevation of the head of the bed (4, 5), a daily sedation break (6) , a daily trial of ventilator weaning (7, 8) , and topical oral chlorhexidine (9) . The quality of evidence supporting the effectiveness of each intervention and the relative importance of each has been questioned. VAP incidence has become a quality indicator in many healthcare systems, leading to comparisons between ICU and, in the United States, may influence reimbursement rates by insurers (10) . The "VAP prevention bundle" is a central component of most critical care patient safety programs.
An important issue relating to reporting VAP incidence is the method of reporting, because this requires a clinical suspicion and the recognition of clinical signs, which introduces the potential for reporting bias in unblinded trials and quality-improvement studies. Diagnostic method can also vary; patients may meet clinical criteria alone or have a microbiologically confirmed diagnosis, which can be made using various approaches that vary in sensitivity and specificity (11) . A recent systematic review of care bundles for ventilated patients concluded that a lack of methodologic rigor in published studies meant it was not possible to conclude that the bundles were either clinically effective or cost-effective (12) . Previous studies have universally reported VAP rates, but reporting of more patient-centered outcomes such as antibiotic use and length of stay have been more variable, thus making it more difficult to estimate the impact of any reduction in VAP on patients and ICUs (13) (14) (15) (16) .
This study set out to establish the effects of systematically implementing a VAP prevention bundle using IHI methodology on VAP rates, antibiotic use, and duration of ICU stay in an ICU with clinical and research interests in VAP and preexisting VAP prevention guidelines.
Setting
This study was conducted in an 18bed, mixed medical-surgical ICU in a Scottish teaching hospital admitting Ͼ1000 patients per year, of whom Ϸ80% require support of at least two organs or invasive ventilation, or both, and 50% stay for 48 hrs or longer. We have been studying VAP since 2005, when we established independent ICU infection surveillance using the Hospitals in Europe Linked for Infection Control through Surveillance methodology (17) . Screening, data collection and reporting was undertaken by a trained, dedicated, fulltime nurse and diagnosis of VAP was made independently by the treating clinical team. Chest radiograph interpretation was undertaken "off-line" and by clinicians who were independent of the treating team. For VAP diagnosis, Hospitals in Europe Linked for Infection Control through Surveillance has a two-stage definition: first, clinically suspected VAP based on clinical criteria; and second, microbiologically confirmed VAP based on further investigations. The details of this process are shown in Figure 1 . Antibiotic use was also recorded prospectively for all patients on a daily basis. We used statistical process control methodology to report rates (18) and before implementing IHI methodology had made attempts to decrease VAP incidence by implementing unit guidelines and protocols including head-of-bed elevation, a nurse-led weaning protocol, and hourly clinical sedation scoring linked to a protocol. Intermittent audits of compliance with these interventions showed variable performance, but we were not recording these processes or feeding them back systematically. From 2005 to 2008, we were unable to decrease the incidence of clinically diagnosed VAP but we had shown that increasing the use of quantitative analysis of bronchoalveolar lavage fluid for microbiological diagnosis resulted in a decrease in the reported incidence of microbiologically confirmed VAP, which was explained by superior test specificity compared with analysis of tracheal aspirates (11) .
Methods and Bundle Description
This study used a before-and-after structure to analyze the effects of implementing a VAP prevention bundle. In 2007 National Health Service Scotland launched the Scottish Patient Safety Pro-gramme in collaboration with the IHI as the first nationwide patient safety program (19) . One key aim was to reduce VAP incidence in Scottish ICUs, and a VAP prevention bundle was developed by the Scottish Intensive Care Society Audit Group for the Scottish Patient Safety Programme (20) . The bundle has five elements: (1) a daily sedation hold; (2) daily trial of ventilator weaning for suitable patients; (3) head-up position; (4) chlorhexidine mouth care; and (5) subglottic secretion drainage using specialized endotracheal tubes. The only elements of the bundle that we had not attempted to implement already were chlorhexidine mouth care and subglottic suction endotracheal tubes, but we had not used the systematic approach to practice change promoted by the IHI for any of the bundle components and were unsure if the Scottish Patient Safety Programme would produce clinically important benefits. We chose to implement four elements of the VAP prevention bundle, namely a daily sedation hold and trial of ventilator weaning for suitable patients (which combined were called "wake and wean"), head-up position, and chlorhexidine mouth care. We did not implement subglottic secretion drainage using specialized endotracheal tubes, because this required frequent endotracheal tube changes and most of our patients were admitted intubated from either the operating theater or the emergency department. The additional cost of specialized tubes meant this was also the most costly bundle element.
The wake and wean algorithm was based on that used in a recent randomized controlled trial (21) . In our unit, the nurse at the bed space was required to assess the patient's suitability for a sedation break and weaning of ventilatory support every morning. Bundle introduction was accompanied by nurse education relating to wake and wean practice. Nurses were asked to follow a checklist each morning that included an assessment of whether they considered the patient suitable for a wake and wean trial and whether they performed the trial. This "process measure" was completed as a checklist on the patient chart each morning. Compliance was defined as whether the checklist was completed without individually assessing whether medical staff agreed with the decision made. When in doubt, the nurse was asked to consult medical staff. Unless there were clinical indications for supine nursing, all patients were placed in a position of at least 30 degrees head-up tilt. Topical buccal 1% chlorhexidine gel was prescribed four times per day for all ventilated patients unless the patients either were allergic to the gel or refused the gel (2% gel is unavailable in the United Kingdom).
Bundle elements were applied using Plan, Do, Study, Act cycles (1) until a method of implementation was identified that maximized compliance. Methods used during implementation included nurse and medical champions, teaching materials, education sessions, bedside cues, changing the 24-hr observation charts, and feedback of compliance at meetings, by e-mail, and with posters. All modifications to improve compliance were led by bedside nursing and medical staff.
Compliance of all patients was audited weekly at unannounced and variable times by an independent, nonclinically trained audit clerk who audited charts from the previous day to minimize observation bias. Compliance was defined as clear documentation either confirming compliance or deciding to avoid a bundle element for clinical reasons. Failure to complete bundle documentation was coded as a lack of compliance. Throughout the study period, standard infection control precautions were in place and were not altered. These included removal of outdoor clothing/white coats by visiting clinicians, single-use aprons for each bedside, bedside alcohol gel, and access to sinks at each bed space for hand decontamination. Regular audit of adherence to these measures showed no major changes or trends throughout the period of study.
Outcome Measures and Analysis Plan
We were interested in whether the introduction of the Scottish Intensive Care Society Audit Group VAP bundle using the IHI approach would decrease the incidence of both clinically diagnosed and microbiologically confirmed VAP, and whether it changed antibiotic use. We also wanted to measure its effect on rates of methicillinresistant Staphylococcus aureus (MRSA) acquisition, another key quality indicator. MRSA acquisition was defined as MRSA cultured from either surveillance swabs or samples taken during investigation of suspected sepsis in a patient who was MRSAnegative at ICU admission based on admission screening swabs or other pre-ICU cultures. All patients were screened at ICU discharge to enable acquisition status to be determined.
We chose duration of mechanical ventilation, ICU stay, and ICU mortality as important patient outcomes that also have important cost implications as secondary end points. We recognized that patients with longer ICU stays are at greater risk for VAP, so we reported outcomes for several patient subcohorts, namely all patients at risk for VAP (ICU stay Ն48 hrs), patients with ICU stay Ն6 days, and patients with ICU stay Ն14 days. Our ICU also reports standardized mortality ratios on an annual basis as part of the Scottish Intensive Care Society Audit Group national audit, which includes all patients admitted to the ICU and compares ultimate hospital mortality to the Acute Physiology and Chronic Health Evaluation II prediction model. We report trends in these over the peri-ods covered by the study as an overall indicator of ICU performance.
Elements of the Scottish Intensive Care Society Audit Group VAP prevention bundle were introduced progressively between February and September 2008. We used our surveillance data from January 2005 to February 2008 as baseline data, from February 2008 to September 2008 as the "run-in" period, and from September 2008 to August 2009 as the "post-VAP prevention bundle implementation" period. We compared the periods before and after the intervention using conventional statistical methods for comparing.
Summary statistics using Z-test to compare proportions, Mann-Whitney U test to compare median values (Prism; Graphpad, LA Jolla, CA), and Poisson regression for incident densities (PASW version 18.0; IBM, Armonk, NY). Changes were also assessed using statistical process control charts using monthly data throughout the period of observation. Patient gender, age, and admission Acute Physiology and Chronic Health Evaluation II score were compared as potential confounders to a before-and-after evaluation. As a service evaluation, ethics committee approval was not required.
RESULTS
During the postimplementation period, compliance with oral chlorhexidine and 30-degree head-up tilt were consistently Ͼ95%. Compliance with the wake and wean element was more difficult to achieve consistently. Full compliance with all elements of the VAP bundle over the post-VAP prevention bundle implementation period was 70%, with 90% of noncompliance attributable to failure to either document or make wake and wean decisions.
During the preintervention period, 2945 patients were admitted, of whom 1460 required Ն48 hrs in the ICU (49.6% patient at-risk rate). During the postintervention period (excluding 554 patients admitted during the run-in phase), 851 patients were admitted, of whom 501 required Ն48 hrs in the ICU (58.9% patient at-risk rate). Considering all admissions, the clinically suspected VAP rate before intervention was 7% (216 VAP events) compared with 5% (43 events) during the postintervention period (absolute risk reduction, 2%; 95% confidence interval [CI], 0.4%-4%; relative risk reduction, 28%; 95% CI, 5%-50%; p ϭ .02). For the patient at-risk populations, the incident density of VAP declined from 32 (95% CI, 27-35) cases per 1000 ventilator days to 12 (95% CI, 9 -15) cases per 1000 ventilator days (p Ͻ .001). Expressed as crude incidence, the proportion of patients with clinically suspected VAP decreased from 15% before intervention to 9% after intervention (absolute risk reduction, 6%; 95% CI, 3%-10%; relative risk reduction, 40%; 95% CI, 20%-67%; p ϭ .001; Table  1 ). These reductions were greater among patients requiring Ն6 days in the ICU (absolute risk reduction, 12%; 95% CI, 6%-18%; relative risk reduction, 44%; 95% CI, 22%-67%) and largest among patients requiring Ն14 days in the ICU (absolute risk reduction, 17%; 95% CI, 6%-27%; relative risk reduction, 35%; 95% CI, 13%-56%). Rates of microbiologically confirmed VAP also decreased in all groups, with the reductions being more marked than for clinical VAP. However, there was a concomitant increase in the use of bronchoscopy, which was a potential confounding factor in this anal-ysis (11) . The microbial etiology of confirmed VAPs is shown in Table 2 , which shows a marked decrease in staphylococcal infection. Although antibiotic use was similar for the entire cohort, among the subgroups with longer stays there was a significant decrease in the number of days of antibiotic therapy. There were no significant differences in duration of mechanical ventilation or ICU stay, but ICU mortality rate was lower after introduction of the VAP prevention bundle, especially for the patient subgroups with longer stays. This was observed despite higher overall admission illness severity (Acute Physiology and Chronic Health Evaluation II score) in the postintervention period. During the postintervention period, more patients admitted for Ն48 hrs required ventilation (77% vs. 83%; p ϭ .002) and the proportion of admission days spent ventilated increased (73% vs. 75%; p ϭ .006). This explained the increased proportion at risk for development of VAP. Despite this, MRSA acquisition decreased from 10% of patients before intervention to 3.6% after intervention (p Ͻ .001). Standardized mortality rates for our entire ICU population trended downward over the period covered by this study from .88 in the first year to .68 in the year of the intervention. Figure 2 shows a "run-chart" illustrating monthly rates of clinically suspected VAP per 1000 ventilator days over the entire period of data collection. Local initiatives before formal bundle implementation had not consistently reduced the monthly incidence of VAP, but this decreased dramatically during the run-in phase and was sustained during the postintervention period.
DISCUSSION
Our data provide compelling evidence that the introduction of the VAP prevention bundle using the IHI approach was associated with a clinically important sustained reduction in the incidence of VAP. Quality-improvement programs, with their aim of embedding practice change within the culture of a unit or organization, do not tend to lend themselves either ethically or practically to analyses other than before and after (e.g., interrupted time series). Although before-and-after evaluations are subject to methodologic criticism, our findings were strengthened by the use of established independent surveillance method- ology, a long baseline and prolonged postintervention periods, and multiple approaches to evaluating the effect on VAP. Specifically, we observed consistent effects irrespective of the method used to define VAP and larger reductions were observed for ICU patient cohorts requiring more prolonged ICU stay, which is biologically plausible because the risk period is longer. Importantly, analysis of data by both summary statistics for before and after and time series analysis with statistical process control methodology revealed consistent results (i.e., a significant reduction in VAP rates after bundle implementation). The time series analysis also appeared to link greatest change with bundle implementation, further supporting a causative association. As for any before-and-after analysis, we cannot completely exclude effects from other changes in practice or policy, but no other relevant systemic alterations were introduced to ICU care during the period of data collection. However, we did not have access to data concerning patterns of antibiotic use before ICU admission, which might have affected both VAP rate and the patterns of infecting organisms.
Our ICU had an interest in VAP before introducing the ventilator bundle and has participated in several studies (11, 22, 23) of this disease, which had not appreciably altered the rate of clinical VAP in the preintervention period, with reducing the probability of Hawthorne effects (24) being responsible for the change seen. These strengths of our data address many of the criticisms made of analyses of quality-improvement programs, especially in relation to reporting bias. Our data provide support for the IHI approach to quality-improvement, particularly because our earlier attempts to reduce VAP incidence had been unsuccessful. The main difference was focusing on high levels of compliance with the bundle elements, which we had not achieved previously. This is consistent with the findings of Hawe et al (13) , who noted improved compliance once VAP prevention measures were actively rather than passively implemented.
Despite the reductions in VAP, we were unable to demonstrate a reduction in duration of mechanical ventilation, even for patient cohorts with longer stays, and overall ICU admission duration remained unchanged. Other issues such as the admission illness severity may be more important determinants of these outcomes, or it could be that the incidence of VAP was too low to influence data for the entire population. We were also unable to achieve Ͼ95% compliance with the wake and wean element of the VAP prevention bundle, which probably correlates most strongly with duration of ventilation. However, we recognized that compliance with this bundle element was influenced more strongly by documentation completeness than other elements. The observed clinical improvements in infection rates despite failure to achieve Ͼ95% compliance with all bundle elements provides further support to the general approach, particularly as efforts before the IHI implementation approach had failed to result in measurable changes. Our next steps include measures to improve practice in this area further and evaluate the impact on patient outcomes. We used an evidence-based approach to antibiotic management of suspected VAP, which comprised early empirical use of broad-spectrum agents until microbiological results were available, at which time de-escalation was encouraged. In our ICU, both Gram-positive (including MRSA) and Gram-negative organisms caused VAP, so our usual treatment regimen included a carbapenem or piperacillin-tazobactam and vancomycin, which were typically continued for 5-7 days unless de-escalation occurred. During the postintervention period, the duration of antibiotic therapy was reduced among the patient cohorts with longer stays, and reached statistical and clinical significance. The exact reasons for this are uncertain, but may be in part because the mean duration of antibiotic use among all patients was relatively short (3 days). We did not have data for antibiotic use after ICU stay, and it is possible that patients with shorter stays completed their courses of antibiotic treatment after ICU discharge, whereas this was less likely for patients with longer stays. Because the incidence of VAP was higher among patients with longer stays, attributable to the longer period of risk and greater exposure to risk factors, we consider it consistent with biological plausibility that this group might experience greater benefit from the qualityimprovement program.
The combination of decreased incidence and duration of antibiotic use indicates a direct effect on drug cost and, likely, indirect benefits on antibiotic stewardship, emergence of resistance, and yeast and Clostridium difficile infections. It was notable that MRSA acquisition rates, a key quality target, decreased significantly.
Part of this reduction was attributable to the marked decrease in pneumonias attributable to Gram-positive organisms ( Table  2) , and Staphylococcus aureus was the most common pneumonia-causing organism in our unit during the study period. It is possible that the dramatic reduction in MRSA acquisition and MRSA VAP observed during the postintervention period was, in part, a result of an overall reduction in antibiotic use in the ICU (25) .
Over the past 5 yrs, we have seen a reduction in standardized mortality ratios for our unit, which we believe is indicative of an increasing standard of care. It is pos-sible that care bundles, including the VAP prevention bundle, have contributed to these improved outcomes given the association between VAP and mortality (2, 26) .
Concerns that changing the diagnostic technique might result in changes in reported VAP rate without affecting the underlying incidence (11) have been addressed in two ways. First, we report the total number of patients meeting clinical criteria for VAP that, although almost certainly overestimating the true incidence of pneumonia, is not susceptible to changes in how samples for culture are obtained (11) . Second, we report our rate of use of invasive vs. noninvasive sampling, and although there was an increase in invasive sampling, this would not have affected the measure of clinical VAP, which was our primary outcome measure. It is notable that use of bronchoscopy remained high, suggesting that the previous bronchoscopy practice change (11) had become well-embedded.
Management of VAP exists in tension between early treatment with empirical broad-spectrum antibiotics and focused therapy based on the results of cultures. The inherent delay in obtaining microbiological results and knowledge that delay in appropriate antibiotics is associated with adverse outcomes (27) tends to result in frequent resorting to antibiotics. As a result, even episodes of suspected VAP that subsequently prove to be culture-negative incur an antibiotic burden and suggest that reductions in clinical VAP as well as culture-positive VAP have a potential positive impact on patients. It is therefore reassuring to see that our reductions in VAP were also associated with an overall reduction in the antibiotic burden experienced by the patients at highest risk for VAP, suggesting that treating clinicians were not simply continuing to treat patients who were no longer labeled as having VAP.
There remain a number of VAP reduction interventions that we have not yet adopted, such as antibacterial-coated endotracheal tubes (28) and subglottic suction (29) . These, combined with more complete adoption of the wake and wean bundle elements, may allow us to achieve further improvements in patient outcomes. Our established statistical process control methodology will provide a robust method of assessing the clinical and cost-effectiveness of introducing these more expensive interventions.
CONCLUSIONS
This study suggests that systematic implementation of a bundle of interventions can reduce the incidence of VAP, with consequent effects on antibiotic use among those at greatest risk. These effects are in addition to those produced by simply having VAP prevention guidelines, a unit interested in studying and preventing VAP, and regular monitoring and feedback of VAP incidence, which have been potential confounders in previous reports of the implementation of VAP prevention bundles.
